Close Menu

NEW YORK (GenomeWeb) – Natera announced today that it has prices its $100 million common stock offering.

The San Carlos, California-based molecular diagnostics firm is offering 5,263,158 shares of common stock at $19 per share. Gross proceeds from the offering would be $100 million, however, the underwriters of the transaction have a 30-day option to purchase an additional 789,473 shares at the offering price.

JP Morgan, Cowen, and Piper Jaffray are acting as joint book-running managers for the offering. Baird and Canaccord Genuity are listed as co-managers for the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.

The Washington Post reports that Philip Leder, who helped uncover how DNA codes for proteins and studied the role of genes in cancer, has died.

Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.

In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.